Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of SHB-02-CD19 1XX anti-CD19 CAR-T cells in relapsed or refractory B-cell malignancies
MOH_2026-03-24_015730Phase 2Not yet recruiting
- Sponsor
- ד"ר ג'ונתן אזנשטיין
- Start
- Mar 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHB-02-CD19 in B-cell malignancy, acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 2 more (3 arms), sponsored by ד"ר ג'ונתן אזנשטיין. Primary endpoints: Safety of SHB-02-CD19, Efficacy of SHB-02-CD19 and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SHB-02-CD19
03
Conditions
B-cell malignancyacute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2026-03-24_015730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-24_015730.